#### Check for updates

#### **OPEN ACCESS**

EDITED BY Herbert Yu, University of Hawaii, United States

#### REVIEWED BY

Jinyi Lang, Sichuan Cancer Hospital, China Yuan-Zheng Xia, China Pharmaceutical University, China Nan Bi, Chinese Academy of Medical Sciences and Peking Union Medical College, China

\*CORRESPONDENCE Conghua Xie chxie\_65@whu.edu.cn Jing Yu yujingrt@163.com

<sup>†</sup>These authors have contributed equally to this work and share first authorship

<sup>‡</sup>These authors have contributed equally to this work and share senior authorship

SPECIALTY SECTION

This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology

RECEIVED 14 April 2022 ACCEPTED 02 August 2022 PUBLISHED 23 August 2022

#### CITATION

Cheng Y, Yang B, Ouyang W, Jie C, Zhang W, Chen G, Zhang J, Yu J and Xie C (2022) Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A realworld investigation. *Front. Oncol.* 12:920047. doi: 10.3389/fonc.2022.920047

# Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A realworld investigation

Yajie Cheng<sup>1,2,3†</sup>, Bin Yang<sup>1,2,3,4†</sup>, Wen Ouyang<sup>1,2,3†</sup>, Chen Jie<sup>1,2,3</sup>, Wei Zhang<sup>1,2,3</sup>, Gang Chen<sup>1,2,3</sup>, Junhong Zhang<sup>1,2,3</sup>, Jing Yu<sup>1,2,3\*†</sup> and Conghua Xie<sup>1,2,3\*†</sup>

<sup>1</sup>Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China, <sup>2</sup>Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China, <sup>3</sup>Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China, <sup>4</sup>Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

**Purpose:** To evaluate the outcomes of immune checkpoint inhibitor (ICI)based treatments versus classical chemotherapy for metastatic non-small cell lung cancer (NSCLC) patients who develop epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance and to explore the population that may benefit from ICI-based therapy.

**Materials and methods:** All patients who had previously received EGFR-TKI therapy at two cancer centers in China and developed resistance to targeted therapies were included. Progression-free survival (PFS) and overall survival (OS) were utilized to evaluate the outcomes of the study cohort.

**Results:** A total of 132 patients were included. The median follow-up time for this cohort was 21.7 months (IQR, 14.8–28.8 months), calculated from the date of EGFR-TKI resistance. The median PFS and OS were 4.9 months (IQR, 2.8–9.2) and 13.5 months (IQR, 6.6–26.5 months), respectively. Multivariate analysis showed that ICI-based therapy could significantly improve OS when compared to the classic chemotherapy (hazard ratio [HR], 0.55; 95% CI, 0.34–0.88; P = 0.01) after adjusting for variables such as gender, age, mutation status, and brain or liver metastasis status. The combined modality of ICI plus chemotherapy could offer a long-term OS benefit in most subgroups, such as young (<65 years) patients, and those without secondary T790M mutations or absence of liver and brain metastases, and the populations with good Eastern Cooperative Oncology Group (ECOG) scores.

**Conclusion:** For patients presenting with EGFR-TKI resistance, ICI-based therapy could offer a more favorable survival than classical chemotherapy.

The combination of ICI with chemotherapy may be the optimal modality for those with good ECOG PS scores.

KEYWORDS

EGFR-TKI resistance, EGFR-sensitive mutations, combined therapy, metastatic NSCLC, immunotherapy

# Introduction

Lung cancer is currently the most prevalent malignancy worldwide (1). In recent years, with the introduction of immune checkpoint inhibitors (ICIs), such as programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) antibodies, the outcomes of metastatic non-small cell lung cancer (NSCLC) have greatly improved (2–4). However, the responses to immunotherapy seem to differ according to differences in the inherent immune microenvironment (5, 6). For example, NSCLC patients without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR<sup>-</sup>/ALK<sup>-</sup>) seem to benefit from immunotherapy, while the response to immunotherapy seems to be poor in those who harbor EGFR-sensitive mutations and ALK rearrangements (EGFR<sup>+</sup>/ALK<sup>+</sup>) (7).

The tumor immune microenvironment (TME) may undergo changes as the disease progresses (8, 9). For example, one study found that NSCLC patients who developed resistance to firstgeneration EGFR tyrosine kinase inhibitors (TKIs) but did not have a secondary T790M mutation might benefit from ICI monotherapy due to an increase in PD-L1 expression and tumor mutation burden (10). Despite the benefits achieved, the results of ICI monotherapy after EGFR-TKI resistance were not yet satisfactory (11, 12).

Recently, a phase II study confirmed that ICI plus chemotherapy could be a promising second-line option for NSCLC patients developing EGFR-TKI resistance but without a secondary T790M mutation (13). However, a subgroup analysis of the IMpower150 showed that the combination of chemotherapy, bevacizumab, and ICI could only improve PFS but did not achieve an OS benefit when compared to bevacizumab plus chemotherapy (14). Therefore, we conducted this investigation of ICI-based therapy versus classic chemotherapy for those that developed EGFR-TKI resistance from two cancer centers in China and to explore the optimal treatment modality.

# Materials and methods

## Study cohort

All metastatic NSCLC patients (n = 110), either squamous or adenocarcinoma, who had previously benefited from EGFR-TKI, including first- and third-generation drugs, and have developed resistance at the Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, were included in this study. They did not receive chemotherapy before or during treatment with EGFR-TKI. The diagnostic criteria of EGFR-TKI resistance were based on radiological or pathological results. In order to match the number of patients who underwent immunotherapy and chemotherapy alone, we additionally included a subset of patients (n = 22) who underwent immunotherapy after EGFR-TKI resistance occurring at the Department of Hubei Cancer Hospital, between September 2018 and July 2020.

This retrospective study was approved by the Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University ethics committee (2021050K). Waiver of informed consent was approved for the aggregated data.

### Treatment

For patients who developed resistance to first-generation EGFR-TKI and had a secondary T790M mutation, the third-generation EGFR-TKI, osimertinib, would be preferred, while patients who were resistant to first-generation EGFR-TKI but do not have secondary T790M mutations, or those who have been resistant to both first- and third-generation EGFR-TKI, would be treated with chemotherapy or chemotherapy combined with ICI. The chemotherapy regimen after EGFR-TKI resistance (first- or third generation) was pemetrexed (500 mg/m<sup>2</sup>, Q3 weeks) in combination with cisplatin (75 mg/m<sup>2</sup>, Q3 weeks) or carboplatin (AUC 5), which was changed to pemetrexed (500 mg/m<sup>2</sup>, Q3 weeks) monotherapy after 4 cycles of doublet chemotherapy (intravenously).

Treatment options for patients receiving ICI-based therapies included ICI monotherapy or a combination of ICI with

Abbreviations: NSCLC, non-small cell lung cancer; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitors; ICI, immune checkpoint inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance scores.

chemotherapy. ICI monotherapy was administered to patients with PS score >1 or those who were intolerant to chemotherapy. The chemotherapy regimens for combined ICIs were pemetrexed (500 mg/m<sup>2</sup>, Q3 weeks) plus cisplatin (75 mg/m<sup>2</sup>, Q3 weeks) or carboplatin (AUC 5). Patients receiving ICI in combination with chemotherapy would enter ICI maintenance therapy after 4 cycles of combined treatments. The details of ICIbased therapy are shown in Supplementary Table S1.

# Evaluation of treatment response and outcome

The mutation status of EGFR in all patients was detected by the next-generation sequencing technology (NGS) based on tumor biopsy specimens. Patients with atypical EGFR mutations were defined as those who harbored concomitant mutations or uncommon EGFR mutations. Treatment response was defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1. Overall survival (OS) was calculated from the date of immunotherapy or chemotherapy to the date of death from any cause or the date of final follow-up. Progression-free survival (PFS) was defined as the period from the date of immunotherapy or chemotherapy initiation to the date of disease progression or death from any cause or final follow-up.

Patients would undergo a comprehensive review after every two cycles of therapy, including imaging evaluations and laboratory tests, such as blood count, biochemical analyses (coagulation profile, and hepatic and renal function), thyroid function, and tumor marker tests.

### Statistical analysis

OS and PFS were evaluated using the Kaplan–Meier method. The log-rank statistic is approximately distributed as a chisquare test statistic with degree of freedom corresponding to the number of comparison groups minus 1. Multivariate Cox proportional hazard analysis was performed to determine the association of different covariates with OS and PFS. All analyses were carried out using SPSS Statistics, version 20.0 (IBM Corp., Armonk, NY). Statistical significance was at  $P \leq 0.05$ . The P values were derived from a two-tailed test.

## Results

# Patient characteristics in the study cohort

From September 2018 to July 2020, a total of 132 metastatic NSCLC patients who developed EGFR-TKI resistance were

included in our study. Their median age was 57 years (interquartile range [IQR], 52–64 years). In terms of treatment modality, 54.5% of patients received ICI-based therapy compared to 45.5% of patients who received chemotherapy alone. Those who received chemotherapy alone were not subsequently treated with ICI because of the accessibility of the medication and their disease. Their median number of treatment cycles was similar, at 6 and 7 cycles, respectively. The ICI-based treatment group showed a longer duration ( $\geq$ 12 months) of EGFR-TKI treatment and a higher proportion of T790M mutations as compared to the chemotherapy group. Their baseline characteristics are presented in Table 1.

#### Outcomes

The median follow-up time was 21.7 months (IQR, 14.8–28.8 months) as of 11 October 2021. The median PFS of the study cohort was 4.9 months (IQR, 2.8–9.2 months), and the PFS at 1 year was 19.0% (95% confidence interval [CI], 12.6–26.3) (Supplementary Figure S1A). Univariate analysis showed that ICI-based therapy has a similar PFS in comparison to chemotherapy alone (P = 0.19, Figure 1A). Multivariate analysis demonstrated that having good Eastern Cooperative Oncology Group (ECOG) scores and absence of brain metastases contained a lower risk of progression; however, ICI-based therapy was not significantly linked to progression improvement (HR, 0.75; 95% CI, 0.49–1.13; P = 0.17) (Table 2).

The median OS was 13.5 months (IQR, 6.6–26.5 months), with 1- and 2-year OS of 55.4% (95% CI, 46.4%–63.6%) and 25.8% (95% CI, 16.9%–35.5%), respectively (Supplementary Figure S1B). ICI-based therapy could show a significant OS advantage over chemotherapy alone, which could achieve a median OS of 17.1 and 12.0 months, respectively (P = 0.02, Figure 1B). Multivariate analysis confirmed that ICI-based therapy was an independent contributor for improving OS (HR, 0.55; 95% CI, 0.34–0.88; P = 0.01). Meanwhile, female, having a good ECOG PS scores, and without brain metastases were also independent predictors for harboring the better OS (Table 2).

## The optimal modality for immunotherapy

To determine the optimal mode of ICI-based therapy, we then performed a comparison of different treatment subgroups. We found that for EGFR-TKI-resistant patients, ICI plus chemotherapy resulted in the maximum improvement in OS relative to chemotherapy alone, yielding a corresponding median OS of 19.7 and 12.0 months, respectively (P = 0.02, Figure 2B); however, it only slightly prolonged median PFS from 5.0 to 5.2 months (P = 0.08, Figure 2A).

TABLE 1 Baseline characteristics of the study cohort.

<table-container>Izhashtany N = 72 (54)demoteny N = 60 (45)Ageopsyses64 (64)7 (74)06514 (04)7 (74)0Sa14 (04)7 (74)0Sa14 (04)2 (43)0Sa4 (61)2 (43)0Small4 (61)2 (43)0Small10 (14)2 (43)0Small10 (14)2 (43)0Small10 (12)3 (40)0Small10 (12)3 (40)0Small10 (12)3 (40)0Small10 (13)13 (17)0Small10 (13)13 (17)0Small10 (13)13 (17)0Small10 (13)4 (67)0Small10 (13)4 (67)0Small10 (13)4 (67)0Small10 (13)10 (13)10Small10 (13)10 (13)10Small1</table-container>	Characteristic	Patients 1	Р			
Age group, years.     45     56     57     14 (194)     13 (217)       Set     14 (194)     13 (217)     58       Male     28 (38.9)     22 (3.3)     0.97       Seratal     44 (61.1)     28 (67.7)     30 (33.7)     30 (33.7)       Smaking     7     7     30 (43.3)     0.32 (37.7)       No     47 (65.3)     34 (67.7)     30 (43.7)       Pathological type     44 (60.1)     28 (67.7)     30 (43.7)       Advancationsma     2 (2.8)     3 (5.7)     7       Pathological type     44 (60.1)     47 (78.3)     64       Advancationsma     2 (2.8)     3 (5.7)     0.24       No     62 (66.1)     47 (78.3)     10 (17.7)     0.24       No     62 (66.1)     47 (78.3)     10 (17.7)     0.24       No     62 (66.1)     47 (78.3)     10 (17.7)     0.24       No     62 (66.1)     47 (63.7)     0.21     10 (17.7)     0.24       No     10 (13.9)     12 (10.7)     12 (17.7)     0.21		ICI-based therapy N = 72 (54.5) chemotherapy N = 60 (45.5)				
eds36 (00)47 (73.)0.7328514 (0.4)13 (0.7)Set14 (0.4)23 (0.3)0.70Panala26 (0.5)23 (0.3)0.70Smoth25 (0.47)26 (0.47)24 (0.3)0.70No25 (0.47)25 (0.47)24 (0.4)0.70Subing27 (0.5)24 (0.5)0.710.71Panala20 (0.5)27 (0.5)0.710.71Supanos all carizona2.623.700.730.71Supanos all carizona2.623.700.730.71No0.103913 (2.7)0.240.700.71No0.103913 (2.7)0.240.700.71No0.104390.700.710.710.71No0.104392.100.710.71No0.104392.100.710.71No0.10392.100.710.71Infold7.07.10.710.710.71Infold7.07.10.710.710.71Infold7.07.10.710.710.71Infold7.07.10.710.710.71Infold7.07.10.710.710.71Infold7.07.10.710.710.71Infold7.07.10.710.710.71Infold7.07.10.710.710.71Infold7.07.10.710.710.71Infold7.07.10.710.71 <td>Age group, years</td> <td></td> <td></td> <td></td>	Age group, years					
esis14 (04)13 (2.7)ser1Ser11Male26 (0.8)26 (0.3)0.97Penale26 (0.4)26 (0.3)0.21Small26 (0.4)26 (0.3)0.21No20 (0.4)26 (0.3)0.21No20 (0.4)26 (0.3)0.21No20 (0.7)27 (0.5)0.81Sector and	<65	58 (80.6)	47 (78.3)	0.75		
SecMain(263)(263)(267)Fenda(264)(267)(267)Solor(263)(267)(267)No(263)(267)(267)(267)No(263)(267)(267)(267)Solor(263)(267)(267)(267)Solor(260)(267)(267)(267)Solor(260)(267)(267)(267)No(260)(267)(267)(267)No(260)(267)(267)(267)No(260)(267)(267)(267)No(260)(267)(267)(267)No(267)(267)(267)(267)Solor(267)(267)(267)(267)Solor(267)(213)(267)(267)Solor(273)(216)(27)(267)Solor(27)(216)(27)(260)Solor(263)(260)(260)(260)Solor(263)(260)(260)(260)Solor(263)(260)(260)(260)Solor(263)(263)(260)(260)Solor(27)(263)(260)(260)Solor(27)(263)(260)(260)Solor(263)(263)(260)(260)Solor(263)(263)(260)(260)Solor(263)(263)(260)(260)Solor(263)	≥65	14 (19.4)	13 (21.7)			
Male26 (38)2 (53)0.97Fende4 (61.)26 (63.)	Sex					
Penale4 (d.1)28 (d.7)Smilling5 (d.7)26 (d.3)0.2 (d.3)Va2 (d.3)2 (d.3)0.2 (d.3)Na0 (d.5)2 (d.3)0.2 (d.3)Patholic0 (d.7)3 (d.6)0.2 (d.3)Summa self cardinoma0 (d.7)3 (d.6)0.2 (d.3)Summa self cardinoma0 (d.7)0.2 (d.3)0.2 (d.3)Na0 (d.0.3)1 (d.1)0.2 (d.3)0.2 (d.3)Na0 (d.0.1)1 (d.0.2)0.2 (d.3)0.2 (d.3)Na0 (d.0.1)1 (d.0.2)0.2 (d.3)0.2 (d.3)Na0 (d.0.1)0.2 (d.3)0.2 (d.3)0.2 (d.3)Eder maters initially1 (d.0.2)2 (d.0.1)0.2 (d.3)Eder maters initially1 (d.0.2)2 (d.0.1)0.2 (d.0.1)Eder maters initially1 (d.0.2)2 (d.0.1)0.2 (d.0.1)Eder maters initially1 (d.0.2)2 (d.0.1)0.2 (d.0.1)Eder maters initially1 (d.0.2)1 (d.0.1)0.2 (d.0.1)Eder maters initially1 (d.0.2)1 (d.0.1)0.2 (d.0.1)Eder maters initially2 (d.0.1)2 (d.0.1)0.2 (d.0.1) <t< td=""><td>Male</td><td>28 (38.9)</td><td>32 (53.3)</td><td>0.97</td></t<>	Male	28 (38.9)	32 (53.3)	0.97		
<table-container>SimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimpleSimp</table-container>	Female	44 (61.1)	28 (46.7)			
Yea25 (34,7)26 (43,3)0.32No0.630.630.63No0.630.670.64Squano call carcinona70 (07.2)57 (95)0.84Squano call carcinona0.20 (0.7)0.21No0.20 (0.7)0.210.21Internationa0.20 (0.7)0.21No0.20 (0.7)0.21No0.20 (0.7)0.21No0.20 (0.7)0.21No0.20 (0.7)0.21No0.20 (0.7)0.21No0.20 (0.7)0.21No0.20 (0.7)0.21Star and that star first barbay:0.21 (0.5)0.21 (0.5)EXIPD alona0.5 (0.8)27 (45)0.641588 alona27 (45)0.21 (0.5)0.41Adota Cartination status at first barbay:0.21 (0.5)0.42Exit FURA27 (37.5)2.1 (3.5)0.43Adota Cartination status at first barbay:0.20 (0.7)0.41Cartination status at first barbay:0.610.200.41Fort FURA6.630.6100.200.41Fortable Cartination status at revelops:0.620.610.61Toward alona Cartination status at revelops:0.620.610.62Toward alona Cartinatio	Smoking					
No47 (63)94 (67)Pathour70 (72)57 (9)0.84Adencarioma70 (72)57 (9)0.84Squanous cell carcinoma2 (2a)3 (5)10Brain metastes intituity10 (13)13 (2.7)0.24No0 (201)47 (78.3)1010Liver metastes intituity10 (13)6 (0.3)1010Ke10 (13)6 (0.3)6 (0.3)1010Ke10 (13)6 (0.3)6 (0.3)1010Ke10 (13)10 (13)12 (13)1010Ke10 (13)12 (13)101010Alstel and70 (75)21 (13)0.4310Alstel and70 (75)21 (13)0.4310Alstel and70 (75)71 (17)101010Caltinb70 (72)71 (17)101010Andro Cancinoma6 (13)6 (100)0.211010Andro Cancinoma11 (13)24 (0.0)0.211010Caltinb70 (23)20 (20)101010Andro Cancinoma15 (0.3)10 (10.7)101010Andro Cancinoma15 (0.3)10 (10.7)101010Town Spice and Cancer10 (10.4)10 (10.7)101010Town Spice and Cancer10 (10.4)10 (10.7)101010Town Spice and Cancer10 (10.2)10 (10.7)10 <td< td=""><td>Yes</td><td>25 (34.7)</td><td>26 (43.3)</td><td>0.32</td></td<>	Yes	25 (34.7)	26 (43.3)	0.32		
Pathological typeNoNoNoAlexance and canceration and carcinoma20 (2a)3 (5)3 (5)Brain material trainNo20 (2a)3 (2a)3 (2a)No10 (2a)10 (2a)10 (2a)2aNo10 (2a)10 (2a)3 (2a)3 (2a)3 (2a)No10 (2a)10 (2a)10 (2a)3 (2a)3 (2a)No10 (2a)10 (2a)10 (2a)3 (2a)3 (2a)No10 (2a)10 (2a)10 (2a)10 (2a)3 (2a)No10 (2a)10 (2a)10 (2a)10 (2a)10 (2a)	No	47 (65.3)	34 (56.7)			
Adenacanional70 (97.2)57 (95.)0.84Squanou cell carcinonal20.81.31.5Istanues assess initially10 (13.9)13 (21.7)0.44No62 (64.1)47 (78.3)0.21No10 (15.3)14 (7.7)0.21No10 (16.7)65 (03.3)0.21Chern actasses initially10 (15.3)65 (03.3)0.21Chern actasses initially10 (13.9)12 (20)0.21Ext9Del alone27 (75.5)21 (35.)0.41AsS8 alone27 (27.5)21 (35.)0.43Aspical EGFR mutations 4.1010 (13.9)12 (20)0.41Fort TK67 (78.7)7 (11.7)0.41Gefinath67 (0.7)7 (11.7)0.41Isolato activations at the teleposy10 (13.9)24 (00.0)0.21Advised fiftee mutations 4.1010 (20.1)12 (20.1)12 (20.1)Isolato activations 4.1013 (20.	Pathological type					
Squamous cell carcinoma2 (2.8)3 (5)IP intrastatus inituitarIP intrastatus inituitarNo0 (30 (3)0 (32 (3)No0 (30 (3)0 (32 (3)Ure metatases inituitar1 (10 (3)0 (40 (7)No0 (30 (3)0 (32 (3)EGR mutation status at first biopy1 (0 (3)1 (20 (3)Exist Role7 (75 (3)0 (13 (3)0 (13 (3)Apricel GGR mutations'0 (13 (3)0 (13 (3)0 (13 (1)First GGR mutations'7 (75 (3)0 (13 (1)0 (13 (1)First GGR mutations'7 (75 (1)0 (13 (1)0 (13 (1)Apricel GGR mutations'7 (75 (1)0 (10 (1)0 (11 (1)Apricel GGR mutations'6 (77 (3)0 (10 (3)0 (11 (1)Apricel GGR mutations'7 (75 (1)0 (10 (2)0 (11 (1)Apricel GGR mutations'6 (67 (3)6 (10 (0)0 (1)Apricel GGR mutations'6 (67 (3)6 (10 (0)0 (1)Advinces motion8 (63 (3)6 (10 (0)0 (1)Advinces motion8 (63 (3)6 (10 (1)0 (1)Advinces motion2 (63 (2)1 (1 (13 (3)0 (1)TypOM positive combined with ExiPDed or L858 (7)1 (6 (22)1 (10 (2)0 (10 (2)TypOM positive combined with ExiPDed or L858 (1)1 (20 (1)0 (10 (2)0 (1)TypOM positive combined with ExiPDed or L858 (1)1 (20 (1)0 (1)0 (1)TypOM positive combined with ExiPDed or L858 (1)1 (20 (1)0 (1)0 (1)TypOM positive com	Adenocarcinoma	70 (97.2)	57 (95)	0.84		
Final statuse initially     10.10,0     10.10,1     0.10,1     0.10,1       No     0.20,0     0.10,1     0.10,1     0.10,1       No     0.10,1     0.10,1     0.10,1     0.10,1       No     0.10,1     0.10,1     0.10,1     0.10,1       No     0.10,1     0.10,1     0.10,1     0.10,1       Standand statistication statisticatistication stat	Squamous cell carcinoma	2 (2.8)	3 (5)			
Yes10 (13)13 (21.7)0.24No0.2 (6.1)47 (78.3)10Iter metases initially11 (15.3)4 (6.7)0.12Yes10 (15.7)6 (93.7)6 (93.7)10ECFE metation status aftrs biops27 (3.7)21 (3.5)0.64Ext19Ded alone27 (3.7)21 (3.0)12 (20)12 (20)Appical ECFR mutations"10 (13.9)12 (20)12 (20)12 (20)Erst ECFT TH7 (9.7)7 (11.7)0.1010 (20)12 (20)Coltinb7 (9.7)7 (11.7)0.1010 (20)12 (20)Iotinb7 (9.7)7 (11.7)0.100.110.11Iotinb5 (18.6)41 (68.3)0.610.110.11Iotinb3 (18.3)44 (40.0)0.910.120.11Iotinb3 (18.3)3 (18.0)0.210.110.11Iotinb3 (18.6)3 (18.6)0.110.110.11Iotinov3 (20)12 (20)10 (10.7)0.110.11Iotinov3 (20)12 (20)10 (10.7)0.110.11Iotinov3 (18.6)3 (30.6)0.110.110.110.11Iotinov3 (20)12 (20)10 (10.7)0.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.110.11 <t< td=""><td>Brain metastases initially</td><td></td><td></td><td></td></t<>	Brain metastases initially					
N62 (8.1)97 (78.3)Liver retatates initially11 (1.5.3)4. (6.7)0. (2.7)Ver12 (1.5.3)4. (6.7)0. (2.7)0. (2.7)KFF mutation status at first biopy57 (8.6.)2.7 (4.5)0. (4.7)0. (2.7)LisSR alone3.6 (8.6.)2.7 (4.5)0. (2.7)0. (2.7)0. (2.7)Abycial CER mutation 's (4.7)10 (1.3)10 (1.3)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7)0. (3.7) <td< td=""><td>Yes</td><td>10 (13.9)</td><td>13 (21.7)</td><td>0.24</td></td<>	Yes	10 (13.9)	13 (21.7)	0.24		
Image: set initial set initial set in the s	No	62 (86.1)	47 (78.3)			
Ys     11 (15.3)     4 (67)     0.12       No     61 (84.7)     56 (93.3)     56 (93.3)       EGFR mutation status at first biopsy     55 (84.6)     27 (45)     0.64       EASBA done     27 (37.5)     21 (33.)     12 (20)       Appical EGFR mutations*     10 (13.9)     12 (20)     12 (20)       First EGFR TKI     7 (87.5)     41 (68.3)     0.43       Edotinb     7 (97.7)     7 (17.7)     0.012 (20)     12 (20)       Pathodical type at re-biopsy     12 (20)     12 (20)     12 (20)       Adenocarcinoma (16.00.0)     10 (13.7)     0.43     13 (13.1)     24 (40.0)     0.91       Lookyd differentiated cancer     6 (8.3)     6 (10.0)     0.91     0.04     10 (15.0)     11 (18.3)     0.91       Undword     15 (0.8)     11 (18.3)     0.49     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (17.1)     10 (17.1)     10 (16.7)     10 (17.1)     10 (17.1)     10 (17.1)     10 (17.1) <td>Liver metastases initially</td> <td></td> <td></td> <td></td>	Liver metastases initially					
N     61 (8.7)     56 (9.3)       EGR mutation status at first biopsy     55 (8.6)     27 (45)     0.4       EASR alone     35 (8.6)     27 (45)     0.4       Abyaia EGR mutations*     10 (30)     12 (30)     1       Abyaia EGR mutations*     10 (30)     12 (30)     1       First EGR-TKI     6     7 (9.7)     7 (17)     1       Gefininb     5 (7.7)     7 (17)     1     1       Icotinb     7 (9.7)     7 (17)     1     1       Icotinb     7 (9.7)     7 (17)     1     1       Icotinb     7 (9.7)     7 (17)     1     1       Icotinb     6 (0.3)     6 (0.0)     0.91       Loctinb     6 (8.3)     6 (0.0)     0.91       Unknown     16 (62.3)     10 (16.7)     1       T790M positive combined with Ext PDEI or L&SSR     16 (62.2)     10 (16.7)     1       T790M positive combined with Ext PDEI or L&SSR     16 (22.2)     16 (23.1)     0.09       Lariburd     7 (73.1)     2 (2 (3.3)     1.6 (2.7)<	Yes	11 (15.3)	4 (6.7)	0.12		
EXF mutation status at first biopsy   35 (48.6)   27 (45)   0.64     LK SPDe Jalone   37 (45.0)   21 (35)   10 (35)   10 (35)     Atypical EGFR mutations*   0 (103.0)   0 (20)   10 (35)   0.64     EK EGFR-TKI   6 (67.8)   4 (68.3)   0.43   0.43     Evaluation   7 (97.7)   7 (11.7)   10 (10.7)   10 (10.7)   10 (10.7)     Fotinb   7 (97.7)   7 (11.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7)   10 (10.7) <td>No</td> <td>61 (84.7)</td> <td>56 (93.3)</td> <td></td>	No	61 (84.7)	56 (93.3)			
K19Del alone     55 (48.6)     27 (45)     0.64       L858R alone     27 (37.5)     21 (35)     10 (13.9)     12 (20)       Appical EGFR mutations*     10 (13.9)     12 (20)     10 (13.9)     12 (20)       First EGFR-TKI     66 (17.8)     41 (68.3)     0.43     6.43       Edotinib     7 (9.7)     7 (11.7)     10 (15.7)     12 (20)     10 (15.7)       Pathological type at re-biopsy     31 (43.1)     24 (40.0)     0.91     6.63.1     6 (10.0)     0.91       Dowly differentiated cancer     6 (8.3)     30 (50.0)     30 (50.0)     10 (16.7)     10 (16.7)       T 790M positive combined with Ex19Del or L858R     16 (22.2)     10 (16.7)     10 (16.7)     10 (16.7)       T 790M positive combined with Ex19Del or L858R     16 (22.2)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7)     10 (16.7) <td< td=""><td>EGFR mutation status at first biopsy</td><td></td><td></td><td></td></td<>	EGFR mutation status at first biopsy					
L858 lone     27 (37.5)     21 (35)       Atypical EGFR mutations*     10 (13.9)     12 (20)       First EGFR-TGI      41 (68.3)     0.43       Findinb     56 (77.8)     41 (68.3)     0.43       Findinb     7 (97.7)     7 (11.7)     100       Lotinb     7 (97.2)     12 (20)     100       Pathological type at re-biopsy     0.12 (30)     100     100       Adenocarcinoma     31 (43.1)     24 (40.0)     0.91       Lowindo     6 (8.3)     6 (10.0)     0.01       Lowindo     6 (8.3)     6 (10.0)     0.01       Lowindo     26 (26.2)     10 (16.7)     100       T90M positive combined with Ex19Del or L858R     16 (22.2)     10 (16.7)     100       T90M negative     27 (37.5)     23 (38.3)     0.09       Duration of EGER-TKI therapy (months)     12     0.09     11       212     27 (26.2)     20 (26.4)     29 (48.3)     0.12       Solometrapy histor     56 (77.8)     50 (85.3)     0.42       No     16 (12.2)	Ex19Del alone	35 (48.6)	27 (45)	0.64		
Appical EGR mutations*   10 (13.9)   12 (20)     First EGR-TKI   64 (16.3.)   0.43     Editinb   7 (9.7)   7 (11.7)     Icotinb   7 (9.7)   12 (20)     Icotinb   7 (9.7)   12 (20)     Data-Jogical type at re-biopsy   12 (40.0)   0.91     Adenocarcinoma   14 (43.1)   24 (40.0)   0.91     Mybid differentiated cancer   6 (8.3)   6 (10.0)   0.91     Mybid differentiated cancer   6 (8.3)   6 (10.0)   0.91     Mybid differentiated cancer   7 (37.5)   23 (38.3)   0.71     T790M positive combined with Ex19Del or L\$58R   16 (22.2)   10 (16.7)   0.91     Vandom   28   15   0.09   0.91     Unknown   20 (36.3)   0.11   12.0   0.11     12 concettype type type type type type type typ	L858R alone	27 (37.5)	21 (35)			
Griftinb   56 (77.8)   41 (68.3)   0.43     Edotinb   7 (9.7)   7 (11.7)     Icotinb   9 (12.5)   12 (20)     Patholization   13 (43.1)   24 (40.0)   0.91     Adenocarcinoma   6 (8.3)   6 (10.0)   0.01     Dualy differentiated cancer   6 (8.3)   6 (10.0)   0.01     Uaknown   35 (48.6)   30 (50.0)   0.01     EGFR mutation status at re-biopsy   16 (22.2)   10 (16.7)   0.01     T790M positive combined with Ex19Del or L858R   16 (22.2)   10 (16.7)   0.09     T790M negative   27 (37.5)   23 (38.3)   0.01     Unknown   14 (19.4)   16 (26.7)   0.09     Duartion of EGFR-TKI therapy (months)   2   29 (48.3)   0.10     <12	Atypical EGFR mutations*	10 (13.9)	12 (20)			
Geftinib     56 (7.8)     41 (68.3)     0.43       Evlotinib     7 (9.7)     7 (1.7)       Icotinib     9 (12.5)     12 (20)       Pathological type at re-biopsy     31 (43.1)     24 (40.0)     0.91       Lowly differentiated cancer     6 (8.3)     6 (10.0)     0.91       Lowly differentiated cancer     5 (48.6)     0 (50.0)     0.91       Duknown     5 (48.6)     0 (50.0)     0.71       T790M positive alone     15 (20.8)     11 (18.3)     0.71       T790M positive combined with Ex19Del or L858R     16 (22.2)     10 (16.7)     0.90       Osimertinib     28     15     0.09       Osimertinib     28     15     0.09       Osimertinib     28     15     0.09       I 2     25 (26.4)     29 (48.3)     0.11       212     47 (73.6)     31 (51.7)     0.91       212     16 (22.2)     16 (23.2)     0.16       213     63 (73.8)     50 (83.3)     0.42       214     16 (26.7)     16 (23.2)     16 (23.2)	First EGFR-TKI					
Erlotinib     T     T       Icotinib     9 (12.5)     12 (20)       Pathological type at re-biopsy     44 (40.0)     0.91       Adenocarcinoma     31 (43.1)     24 (40.0)     0.91       Lowly differentiated cancer     6 (8.3)     6 (10.0)     0.91       Consortinoma     35 (48.6)     30 (50.0)     0.71       T90M positive alone     15 (20.8)     11 (18.3)     0.71       T790M positive combined with Ex19Del or L858R     16 (22.2)     10 (16.7)     0.09       Outarion of EGFR-TKI therapy (months)     28     15     0.09       Duration of EGFR-TKI therapy (months)     21     47 (73.6)     31 (51.7)     0.11       ≥12     47 (73.6)     16 (22.2)     10 (16.7)     0.12     0.16     0.12     0.16     0.12	Gefitinib	56 (77.8)	41 (68.3)	0.43		
Lotinb     9 (12.5)     12 (20)       Pathological type at re-biopsy	Erlotinib	7 (9.7)	7 (11.7)			
Pathological type at re-biopsy   Adenocarcinoma   31 (43.1)   24 (40.0)   0.91     Lowly differentiated cancer   6 (8.3)   6 (10.0)   0.91     Unknown   35 (48.6)   30 (50.0)   0     EGFR mutation status at re-biopsy   11 (18.3)   0.71   0.71     T790M positive alone   15 (22.2)   10 (16.7)   0.71     T790M positive combined with Ex19Del or L858R   16 (22.2)   10 (16.7)   0.71     T790M positive combined with Ex19Del or L858R   16 (22.2)   10 (16.7)   0.71     T790M positive combined with Ex19Del or L858R   16 (22.2)   10 (16.7)   0.71     T790M positive combined with Ex19Del or L858R   16 (22.2)   10 (16.7)   0.71     T790M positive combined with Ex19Del or L858R   16 (22.2)   10 (16.7)   0.71     Osimertinib   28   15   0.09     Duration of EGFR-TKI therapy (months)   2   2 (2 (48.3)   0.11     ≥12   47 (73.6)   31 (51.7)   2     Radiotherapy history   16 (12.2)   10 (16.7)   0.20     Kes   56 (77.8)   50 (83.3)   0.42     ECOG score   1	Icotinib	9 (12.5)	12 (20)			
Adenotarionma   31 (43.1)   24 (40.0)   0.91     Lowly differentiated cancer   6 (8.3)   6 (10.0)     Unknown   35 (48.6)   30 (50.0)     EGFR mutation status at re-biopsy   7   7790M positive alone   15 (20.8)   11 (18.3)   0.71     T790M positive combined with Ex19Del or L858R   16 (22.2)   10 (16.7)   7     T790M negative   27 (37.5)   23 (38.3)   1     Unknown   14 (19.4)   16 (26.7)   0.09     Osimertnib   28   15   0.09     Duration of EGFR-TKI therapy (months)   21   25 (26.4)   29 (48.3)   0.11     ≥12   27 (37.6)   31 (51.7)   21   21   0.21     Radiotherapy history   2   25 (26.4)   29 (48.3)   0.11     ≥12   47 (73.6)   31 (51.7)   21   21   0.21     Radiotherapy history   16 (12.2)   10 (16.7)   0.42   2     Ves   56 (77.8)   50 (83.3)   0.42   2   0.14   2     ECOG score   1   15 (20.8)   9 (15.0)   0.39   2   15 (2	Pathological type at re-biopsy					
Lowly differentiated cancer     6 (8.3)     6 (10.0)       Unknown     35 (48.6)     30 (50.0)       EGFR mutation status at re-biopsy     7790M positive alone     15 (20.8)     11 (18.3)     0.71       T790M positive combined with Ex19Del or L858R     16 (22.2)     10 (16.7)     77       T790M negative     27 (37.5)     23 (38.3)     0.71       T790M negative     27 (37.5)     23 (38.3)     0.71       Osimertinib     28     16 (25.7)     0.09       Osimertinib     28     0.97     0.97       Outation of EGFR-TKI therapy (months)     21     25 (26.4)     29 (48.3)     0.11       ≥12     47 (73.6)     31 (51.7)     16 (12.2)     0.10 (16.7)     16 (12.2)       Radiotherapy history     2     16 (12.2)     10 (16.7)     16 (12.2)     0.01 (16.7)       ECOG score     1     1.0 (16.7)     10 (16.7)     10 (16.7)     16 (12.2)     10 (16.7)     10 (16.7)       ECOG score     1     1.0 (16.7)     1.0 (16.7)     1.0 (16.7)     1.0 (16.7)     1.0 (16.7)     1.0 (16.7)     1.0 (16.7	Adenocarcinoma	31 (43.1)	24 (40.0)	0.91		
Unknown     35 (48.6)     30 (50.0)       EGFR mutation status at re-biopsy     5 (20.8)     11 (18.3)     0.71       T 790M positive alone     15 (20.8)     10 (16.7)     0.71       T790M positive combined with Ex19Del or L858R     16 (22.2)     10 (16.7)     0.71       T790M negative     27 (37.5)     23 (38.3)     0.71       Unknown     14 (19.4)     16 (26.7)     0.09       Duration of EGFR-TKI therapy (months)     28     15     0.09       ≥12     25 (26.4)     29 (48.3)     0.11       ≥12     47 (73.6)     31 (51.7)     0.42       Radiotherapy history     16 (12.2)     10 (16.7)     0.42       Vos     16 (12.2)     10 (16.7)     0.42       ECOG score     1     10 (16.7)     0.42       1     57 (79.2)     51 (85.0)     0.39       2     15 (20.8)     9 (15.0)     0.42       2     15 (20.8)     9 (15.0)     0.42       2     16 (12.2)     10 (16.7)     0.42       2     16 (20.8)     9 (15.0)	Lowly differentiated cancer	6 (8.3)	6 (10.0)			
EGFR mutation status at re-biopsy   15 (20.8)   11 (18.3)   0.71     T790M positive combined with Ex19Del or L858R   16 (22.2)   10 (16.7)   10 (16.7)     T790M negative combined with Ex19Del or L858R   27 (37.5)   23 (38.3)   10 (16.7)     T790M negative combined with Ex19Del or L858R   27 (37.5)   23 (38.3)   10 (16.7)     Oximertinib   28   15   0.09     Duration of EGFR-TKI therapy (months)   2   16 (26.7)   0.11     ≥12   25 (26.4)   29 (48.3)   0.11     ≥12   47 (73.6)   31 (51.7)   16 (22.7)     Residue trapy (months)     Fees (56 (77.8)   50 (83.3)   0.42     No   16 (12.2)   10 (16.7)   14 (19.4)     ECOC score     1   57 (79.2)   51 (85.0)   0.39     2   15 (20.8)   9 (15.0)   0.39     2   15 (20.8)   9 (15.0)   1.5 (20.8)   9 (15.0)     PL-L1 expression	Unknown	35 (48.6)	30 (50.0)			
T 790M positive alone   15 (20.8)   11 (18.3)   0.71     T 790M positive combined with Ex19Del or L858R   16 (22.2)   10 (16.7)     T 790M negative   27 (37.5)   23 (38.3)     Unknown   14 (19.4)   16 (26.7)     Osimertinib   28   15   0.09     Duration of EGFR-TKI therapy (months)   2   29 (48.3)   0.11     ≥12   25 (26.4)   29 (48.3)   0.11     ≥12   47 (73.6)   31 (51.7)   16 (22.2)     Radiotherapy history   16 (22.2)   10 (16.7)   11     Yes   56 (77.8)   50 (83.3)   0.42     No   16 (22.2)   10 (16.7)   12     ECOG score   10 (16.7)   10 (16.7)   12     1   57 (79.2)   51 (85.0)   0.42     2   16 (22.0)   10 (16.7)   13     2   15 (20.8)   9 (15.0)   14     2   16 (22.0)   10 (16.7)   14     1   57 (79.2)   51 (85.0)   0.39     2   15 (20.8)   9 (15.0)   14     PD-L1 expression   15	EGFR mutation status at re-biopsy					
T790M negative   27 (37.5)   23 (38.3)     Unknown   14 (19.4)   16 (26.7)     Osimertinib   28   15   0.09     Duration of EGFR-TKI therapy (months)   25 (26.4)   29 (48.3)   0.11     ≥12   25 (26.4)   29 (48.3)   0.11     ≥12   47 (73.6)   31 (51.7)   10     Radiotherapy history   56 (77.8)   50 (83.3)   0.42     Yes   56 (77.8)   50 (83.3)   0.42     No   16 (12.2)   10 (16.7)   10     ECOG score   1   15 (20.8)   9 (15.0)     1   57 (79.2)   51 (85.0)   0.39     2   15 (20.8)   9 (15.0)     PD-L1 expression   6 (5 to 12)   7 (6 to 10)	T 790M positive alone T790M positive combined with Ex19Del or L858R	15 (20.8) 16 (22.2)	11 (18.3) 10 (16.7)	0.71		
Osimertinib 28 15 0.09   Duration of EGFR-TKI therapy (months) 21 25 (26.4) 29 (48.3) 0.11   ≥12 27 (73.6) 31 (51.7) 10 (16.7) 10 (16.7)   Radiotherapy history 56 (77.8) 50 (83.3) 0.42   Yes 56 (77.8) 50 (83.3) 0.42   No 16 (12.2) 10 (16.7) 10   ECOG score 1 57 (79.2) 51 (85.0) 0.39   2 15 (20.8) 9 (15.0) 0.39   Therapy cycles (IQR) 6 (5 to 12) 7 (6 to 10)   PD-L1 expression 55 50 (83.2) 50 (83.2)	T790M negative Unknown	27 (37.5) 14 (19.4)	23 (38.3) 16 (26.7)			
Duration of EGFR-TKI therapy (months)   25 (26.4)   29 (48.3)   0.11     ≥12   47 (73.6)   31 (51.7)     Radiotherapy history   56 (77.8)   50 (83.3)   0.42     Yes   56 (77.8)   50 (83.3)   0.42     No   16 (12.2)   10 (16.7)   10     ECOG score   1   57 (79.2)   51 (85.0)   0.39     2   15 (20.8)   9 (15.0)   0.39     Therapy cycles (IQR)   6 (5 to 12)   7 (6 to 10)   T	Osimertinib	28	15	0.09		
$<12$ $25 (26.4)$ $29 (48.3)$ $0.11$ $\geq 12$ $47 (73.6)$ $31 (51.7)$ Radiotherapy history $56 (77.8)$ $50 (83.3)$ $0.42$ No $16 (12.2)$ $10 (16.7)$ $0.10$ ECOG score1 $57 (79.2)$ $51 (85.0)$ $0.39$ 2 $15 (20.8)$ $9 (15.0)$ $0.39$ Therapy cycles (IQR) $6 (5 to 12)$ $7 (6 to 10)$ PD-L1 expression	Duration of EGFR-TKI therapy (months)					
≥12 47 (73.6) 31 (51.7)   Radiotherapy history 56 (77.8) 50 (83.3) 0.42   Yes 56 (77.8) 10 (16.7)   ECOG score 16 (12.2) 10 (16.7)   1 57 (79.2) 51 (85.0) 0.39   2 15 (20.8) 9 (15.0)   Therapy cycles (IQR) 6 (5 to 12) 7 (6 to 10)	<12	25 (26.4)	29 (48.3)	0.11		
Radiotherapy history   56 (77.8)   50 (83.3)   0.42     Yes   56 (77.8)   10 (16.7)   10 (16.7)     ECOG score   1   57 (79.2)   51 (85.0)   0.39     2   15 (20.8)   9 (15.0)   0     Therapy cycles (IQR)   6 (5 to 12)   7 (6 to 10)   PD-L1 expression	≥12	47 (73.6)	31 (51.7)			
Yes     56 (77.8)     50 (83.3)     0.42       No     16 (12.2)     10 (16.7)     10 (16.7)       ECOG score     7     7     7     9     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10     10<	Radiotherapy history					
No     16 (12.2)     10 (16.7)       ECOG score     1     57 (79.2)     51 (85.0)     0.39       2     15 (20.8)     9 (15.0)     1       Therapy cycles (IQR)     6 (5 to 12)     7 (6 to 10)     PD-L1 expression	Yes	56 (77.8)	50 (83.3)	0.42		
ECOG score   1   57 (79.2)   51 (85.0)   0.39     2   15 (20.8)   9 (15.0)   1     Therapy cycles (IQR)   6 (5 to 12)   7 (6 to 10)   1     PD-L1 expression   1   1   1   1	No	16 (12.2)	10 (16.7)			
1     57 (79.2)     51 (85.0)     0.39       2     15 (20.8)     9 (15.0)     15       Therapy cycles (IQR)     6 (5 to 12)     7 (6 to 10)     PD-L1 expression	ECOG score					
2     15 (20.8)     9 (15.0)       Therapy cycles (IQR)     6 (5 to 12)     7 (6 to 10)       PD-L1 expression     7     7 (10)	1	57 (79.2)	51 (85.0)	0.39		
Therapy cycles (IQR)     6 (5 to 12)     7 (6 to 10)       PD-L1 expression     7	2	15 (20.8)	9 (15.0)			
PD-L1 expression	Therapy cycles (IQR)	6 (5 to 12)	7 (6 to 10)			
	PD-L1 expression					

(Continued)

TABLE 1 Continued

Characteristic	Patients 1	Р		
	ICI-based therapy N = 72 (54.5)	chemotherapy N = 60 (45.5)		
	<1%	22 (30.6)	15 (25.0)	0.73
	1%-49%	12 (16.7)	10 (16.7)	
	≥50%	3 (4.1)	5 (8.3)	
	Unknown	35 (48.6)	30 (50.0)	

IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group; CNS, central nervous system; ICI, immune checkpoint inhibitor; EGFR, epidermal growth factor receptor. \*Including patients with concomitant mutations and/or uncommon EGFR mutations.

Furthermore, we concluded that patients who were younger (<65 years), have no T790M secondary mutations, or have good ECOG PS scores and those without brain or liver metastases were all the beneficiaries of the ICI-chemotherapy combination modality (Table 3).

## Toxicities

The ICI-based treatment had similar treatment-related toxicities compared to chemotherapy alone, the most common of which included neutropenia, anemia, and fatigue, with incidences of 58.3% (N = 42) versus 61.7% (N = 37), 48.6% (N = 35) versus 65.0% (N = 39), and 19.4% (N = 14) versus 25% (N = 15), respectively.

Grade 3 or higher toxicities occurred mainly in chemotherapy-containing regimens (ICI plus chemotherapy or chemotherapy alone), with neutropenia being the most common at 7.4% (N = 9), followed by thrombocytopenia at 9.1% (N = 11). For those treated with ICI monotherapy, no grade 3 or higher toxicities were observed.

A patient developed G3 dermatitis after receiving two cycles of ICI plus chemotherapy. After discontinuation and symptomatic management, the severity of the dermatitis returned to G1.

# Discussion

To date, ICI-based therapy is regarded as a promising second-line option for metastatic NSCLC with EGFR-TKI resistance, but the optimal modality is still under investigation. Our investigation has shown that ICI-based therapy is a superior treatment to conventional chemotherapy, and ICI combined with chemotherapy should be the recommended treatment for those with good ECOG PS scores, without secondary T790M mutations, and without initial brain metastases or liver metastases.

Previous studies have confirmed a lack of response to ICIs in metastatic NSCLC patients with EGFR mutations, and one of the potential mechanisms could be the low expression of PD-L1 or absence of infiltrating T cells in the TME (6, 7, 15). However, as tumors continue to evolve, the TME may change accordingly and, therefore, EGFR-TKI resistance might enhance the response to ICIs (8, 9, 13). As reported from the EGFR<sup>+</sup>/ALK<sup>+</sup> cohort in the ATLANTIC study, the use of durvalumab monotherapy could provide a favorable outcome in EGFR<sup>+</sup>/ ALK<sup>+</sup> patients, with a median PFS and OS of 1.9 and 13.3 months, respectively, if PD-L1 expression is greater than 25% (16, 17). In the present study, patients receiving immunotherapy achieved PFS and OS of 4.9 and 17.1 months, respectively, which



Comparison of progression-free survival (A) and overall survival (B) for patients who developed EGFR-TKI resistance treated with immunotherapy and chemotherapy alone. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor

Variable		PFS		OS			
	HR	95% CI	P value	HR	95% CI	P value	
Sex							
Female Male	Reference 1.31	0.86-1.97	0.21	Reference 1.94	1.24-3.03	0.00	
Age, years							
<65 ≥65	Reference 1.38	0.81-2.33	0.24	Reference 0.97	0.53-1.77	0.92	
EGFR mutation status at first biop	osy						
Atypical EGFR mutations L858R alone Ex19Del alone	Reference 1.25 0.95	0.69-2.28 0.51-1.78	0.47 0.88	Reference 0.94 0.89	0.49-1.82 0.44-1.79	0.86 0.74	
Secondary T790M mutation							
Positive Negative vs.	Reference 0.85	0.56-1.30	0.45	Reference0.93	0.57-1.53	0.78	
Duration of EGFR-TKI therapy, n	nonths						
≥12 <12	Reference 0.79	0.50-1.23	0.30	Reference 0.75	0.45-1.27	0.27	
ECOG PS							
>1 1	Reference 0.32	0.18-0.56	0.00	Reference 0.34	0.19-0.63	0.00	
Brain metastases							
Yes No	Reference 0.66	0.45-0.98	0.04	Reference 0.52	0.33-0.81	0.00	
Liver metastases							
Yes No	Reference 0.67	0.38-1.18	0.17	Reference 0.58	0.31-1.08	0.09	
Modality							
CT ICI-based therapy	Reference 0.75	0.49-1.13	0.17	0.55	0.34-0.88	0.01	

TABLE 2 Multivariable analysis of PFS and OS in patients who received ICI-based therapy and chemotherapy after developing EGFR-TKI resistance.

PFS, progression-free survival; OS, overall survival; EGFR, epidermal growth factor receptor; HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group; CT, chemotherapy. \*Including patients harboring concomitant mutations or uncommon EGFR mutations.

The bolded numbers represent the results at P<0.05.



#### FIGURE 2

Comparison of progression-free survival (A) and overall survival (B) in the ICI combination chemotherapy versus the chemotherapy alone after EGFR-TKI resistance. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; ICI, immune checkpoint inhibitor; CT, chemotherapy.

Subgroups	No. of patients		HR for relapse(95% CI)	1-year PFS%		P value	HR for death(95% CI)	2-year OS%		P value
Overall	61	60	0.71 (0.48-1.05)	25.7	14.2	0.08	0.58 (0.37-0.91)	36.2	15.5	0.02
≥65 years	12	13	1.02 (0.43-2.45)	15.0	23.1	0.96	0.96 (0.34-2.74)	0.0	19.2	0.94
<65 years	49	47	0.69 (0.44-1.07)	27.4	11.6	0.09	0.55 (0.33-0.91)	39.2	14.3	0.02
T790M positive	28	22	0.56 (0.30-1.67)	33.6	9.6	0.07	0.66 (0.32-1.35)	35.9	21.2	0.29
T790M negative	33	38	0.88 (0.53-1.45)	19.8	16.7	0.60	0.54 (0.29-0.98)	36.4	10.2	0.04
ECOG PS =1	49	51	0.63 (0.40-0.98)	31.1	14.7	0.04	0.50 (0.30-0.84)	40.7	16.2	0.01
ECOG PS >1	12	9	1.05 (0.40-2.74)	0.00	11.1	0.92	0.81 (0.29-2.26)	0.0	11.1	0.69
Brain metastasis	20	23	0.58 (0.30-1.14)	27.1	0.00	0.11	0.73 (0.37-1.44)	16.7	15.7	0.35
No brain metastasis	41	37	0.83 (0.51-1.37)	24.7	23.7	0.47	0.50 (0.27-0.93)	50.6	16.4	0.03
Liver metastasis	18	7	0.52 (0.20-1.39)	7.5	0.0	0.19	0.36 (0.13-1.03)	14.0	0.0	0.05
No liver metastasis	43	53	0.62 (0.40-0.98)	32.4	15.8	0.04	0.48 (0.27-0.83)	46.2	17.3	0.01

TABLE 3 Subgroup analysis of the outcome of patients receiving ICI in combination with chemotherapy and chemotherapy alone.

(----

ICI, immune checkpoint inhibitor; CT, chemotherapy; HR, hazard ratio; ECOG, PFS, progression-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group.

seemed to be superior to those reported from ATLANTIC, even when PD-L1 expression could not be clarified. In this cohort, more than 90% of ICI modalities were ICI combined with chemotherapy, which would be a possible reason for the better prognosis.

Previous studies have shown that the combination of cytotoxic chemotherapy agents and immunotherapy could increase the possibility of de novo antigen cross-presentation in tumor tissues (18), downregulate the expression of immunosuppressive cells (19), enhance the infiltration of effector T cells (20), and ultimately, improve the response to immunotherapy (4, 21-23). Notably, an important recent singlearm phase II study showed that in EGFR-TKI-resistant NSCLC, the regime of ICI combined with chemotherapy could result in a favorable objective remission rate (ORR, 50%), PFS (7 months), and OS (23.5 months) (13). A retrospective study has also identified the value of ICI combination chemotherapy in metastatic NSCLC after the advent of EGFR-TKI resistance (24). In our study, ICI plus chemotherapy resulted in a PFS of 5.2 months and an OS of 19.7 months, respectively. Our data and the results of that prospective study may suggest that even in EGFR-TKI-resistant populations, the combination of chemotherapy and ICI could provide a good treatment response.

Previous literature has reported that chemotherapy alone could be the best modality when resistance to EGFR-TKI occurred (25). In this study, we compared head-to-head the outcomes of ICI-based therapy and chemotherapy alone and confirmed a significant prognostic advantage of ICI-based therapy, which was mainly reflected in the OS benefit (26, 27).

The lack of sufficient tissue samples for exploratory analysis is a limitation of this study. Therefore, we were only able to test a limited number of specimens for PD-L1 status prior to ICI treatment, and the results showed no significant difference in the proportion of patients with positive expression between the two groups. Therefore, further studies are needed to confirm whether PD-L1 status could predict the superiority of later-line ICI over chemotherapy. In addition, the heterogeneity of the immunotherapy regimens is also a shortcoming of this study. A series of published studies had shown that the ICI regimens in this study had a similar efficacy in NSCLC (23, 28, 29). Therefore, these inconsistent regimens might not significantly affect our outcomes.

# Conclusion

ICI-based therapy is a promising option for NSCLC developing EGFR-TKI resistance. For those with good ECOG PS scores, no secondary T790M mutations, and without initial brain metastases or liver metastases, ICI combined with chemotherapy should be the optimal modality.

# Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

# Ethics statement

The studies involving human participants were reviewed and approved by Zhongnan Hospital of Wuhan University ethics committee. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

# Author contributions

YC and JY: data collection, conception and writing of the manuscript; OW: conception and review of the manuscript; BY: data collection and review of the manuscript; CJ, WZ, and GC: review of the manuscript; CX and JZ: advice and review of the manuscript. All authors contributed to the article and approved the submitted version.

# Funding

This study was funded by the National Natural Science Foundation of China (grant no. 81972852) and Health Commission of Hubei Province Scientific Research Project (grant no. WJ2021F108).

# Acknowledgments

We thank Dr. Yong Yang (Fujian Union Hospital) for providing advice on study design.

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fonc.2022.920047/full#supplementary-material

# References

1. Siegel RL, Miller KD HE, Fuchs A. Cancer statistics, 2021. CA Cancer J Clin (2021) 71:7–33. doi: 10.3322/caac.21654

2. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. KEYNOTE-024 investigators. pembrolizumab versus chemotherapy for PD-L1-Positive non-Small-Cell lung cancer. *N Engl J Med* (2016) 375:1823–33. doi: 10.1056/NEJMoa1606774

3. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. KEYNOTE-042 investigators. pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. *Lancet* (2019) 393:1819–30. doi: 10.1016/S0140-6736(18)32409-7

4. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. KEYNOTE-189 investigators. pembrolizumab plus chemotherapy in metastatic non-Small-Cell lung cancer. *N Engl J Med* (2018) 378:2078–92. doi: 10.1056/NEJMoa1801005

5. Takashima Y, Sakakibara-Konishi J, Hatanaka Y, Hatanaka KC, Ohhara Y, Oizumi S, et al. Clinicopathologic features and immune microenvironment of nonsmall-cell lung cancer with primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors. *Clin Lung Cancer* (2018) 19:352–9. doi: 10.1016/ j.cllc.2018.02.004

6. Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenegre A, Robinet G, et al. Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer. *Target Oncol* (2017) 12:563–9. doi: 10.1007/s11523-017-0510-9

7. Liu SY, Dong ZY, Wu SP, Xie Z, Yan LX, Li YF, et al. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. *Lung Cancer* (2018) 125:86–92. doi: 10.1016/j.lungcan.2018.09.010

8. Isomoto K, Haratani K, Hayashi H, Shimizu S, Tomida S, Niwa T, et al. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer. *Clin Cancer Res* (2020) 26:2037–46. doi: 10.1158/1078-0432.CCR-19-2027

9. Fang Y, Wang Y, Zeng D, Zhi S, Shu T, Huang N, et al. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment

in EGFR/ALK-positive non-small-cell lung cancer. Oncoimmunology (2021) 10:1951019. doi: 10.1080/2162402X.2021

10. Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. *Ann Oncol* (2017) 28:1532–9. doi: 10.1093/annonc/mdx183

11. Qiao M, Jiang T, Liu X, Mao S, Zhou F, Li X, et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: Dusk or dawn? *J Thorac Oncol* (2021) 16:1267–88. doi: 10.1016/j.jtho.2021.04.003

12. Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, et al. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. *Cancer* (2019) 125:1038–49. doi: 10.1002/cncr.31871

13. Jiang T, Wang P, Zhang J, Zhao Y, Zhou J, Fan Y, et al. Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: A multicenter phase-II trial. *Signal Transduct Target Ther* (2021) 15:355. doi: 10.1038/s41392-021-00751-9

14. Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. *Lancet Respir Med* (2019) 7:387–401. doi: 10.1016/S2213-2600(19)30084-0

15. Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis. *Clin Cancer Res* (2016) 15:22:4585–93. doi: 10.1158/1078-0432.CCR-15-3101

16. Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, et al. ATLANTIC investigators. durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. *Lancet Oncol* (2018) 19:521–36. doi: 10.1016/S1470-2045(18)30144-X

17. Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, et al. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. Lung Cancer (2020) 147:137–42. doi: 10.1016/j.lungcan.2020.06.032

18. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. *Cell Death Differ* (2014) 21:15–25. doi: 10.1038/cdd.2013.67

19. Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. *Oncoimmunology* (2017) 6:e1331807. doi: 10.1080/2162402X.2017.1331807

20. Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. *Cancer Immunol Immunother* (2011) 60:1227-42. doi: 10.1007/s00262-011-1020-8

21. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. KEYNOTE-407 investigators. pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med* (2018) 379:2040–51. doi: 10.1056/NEJMoa1810865

22. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. IMpower150 study group. atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med* (2018) 378:2288–301. doi: 10.1056/NEJMoa1716948

23. Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): A randomised, open-label, multicentre, phase 3 trial. *Lancet Respir Med* (2021) 9:305–14. doi: 10.1016/S2213-2600(20)30365-9

24. Tian T, Yu M, Li J, Jiang M, Ma D, Tang S, et al. Front-line ICI-based combination therapy post-TKI resistance may improve survival in NSCLC patients with EGFR mutation. *Front Oncol* (2021) 11:739090. doi: 10.3389/fonc.2021.739090

25. Wu JY, Shih JY, Yang CH, Chen KY, Ho CC, Yu CJ, et al. Second-line treatments after first-line gefitinib therapy in advanced non-small cell lung cancer. *Int J Cancer* (2010) 1:126:247–55. doi: 10.1002/ijc.24657

26. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. *J Clin Oncol* (2019) 37:537–46. doi: 10.1200/ JCO.18.00149

27. Mouritzen MT, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A, et al. Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced NSCLC-real world efficacy. *Cancers* (*Basel*) (2021) 28:13:4846. doi: 10.3390/cancers13194846

28. Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). *J Thorac Oncol* (2020) 15:1636–46. doi: 10.1016/j.jtho.2020.07.014

29. Choe EA, Cha YJ, Kim JH, Pyo KH, Hong MH, Park SY, et al. Dynamic changes in PD-L1 expression and CD8 $^+$  T cell infiltration in non-small cell lung cancer following chemoradiation therapy. *Lung Cancer* (2019) 136:30–6. doi: 10.1016/j.lungcan.2019.07.027

#### COPYRIGHT

© 2022 Cheng, Yang, Ouyang, Jie, Zhang, Chen, Zhang, Yu and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author (s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.